Furthermore, AURKA inhibitor PHA680632 [152] and MLN8237 [153], AURKB inhibitor AZD1152 [154] enhanced tumor response to radiotherapy in p53-deficient cancer cells, atypical teratoid/rhaboid tumors and androgen-resistant prostate cancer respectively. Here, AURKA is linked to neoplasm.